At the upcoming event there will be Insightful presentation on Hypertension from a panel of Eminent Doctors and the Unveiling of “Take Charge at 18′ Movement in the World’s 1st Hypertension Awareness Symbol – The BP Logo, The Gateway of India will be adorned with lights up and enthrall the audience with a 3D projection video.

Addressing the gathering will be by Dr. Agam Vora (Hon. General Secretary-API), Dr Milind Nadkar (President-API), Dr. Shashank Joshi (Editor in Chief, API Textbook of Medicine), Dr Ashok Kripalani (Consultant Nephrologist), Dr Mangesh Tiwaskar (Honorary Editor Journal of API JAPI) Dr Nihar Mehta (Interventional Cardiologist) and a host of other dignitaries.

The Glenmark ‘TAKE CHARGE AT 18’ Movement and Initiative will help  Combat Hypertension Ignorance Among Young Adults in India and will be a breakthrough benchmark in the Industry.

The Glenmark Pharmaceuticals’ Annual General Meeting  (AGM) will be also be held on 27th of September, 2024- Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd. told NH.

Glenmark Pharmaceuticals is primarily engaged in the business of development, manufacturing and marketing of pharmaceutical products. The company is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and over-the-counter (OTC) segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.

In the FY24 annual report, Glenmark Pharmaceuticals said strategic milestones anticipated in FY25 include achieving clinical Proof of Concept for ISB 1442 and/ or ISB 2001, marking major advancements in patient care and therapeutic efficacy. These milestones would not only validate the company’s research and development efforts but also reinforce leadership in driving innovation within the pharmaceutical industry. IGI’s strategic roadmap outlines clear objectives for the upcoming fiscal years, the company said.